Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)GlobeNewsWire • 11/27/19
Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)GlobeNewsWire • 11/20/19
Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)GlobeNewsWire • 11/18/19
Seelos Therapeutics to Participate in Upcoming Investor Conference in NovemberGlobeNewsWire • 10/18/19
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory ConsultantGlobeNewsWire • 10/15/19
Seelos Therapeutics to Participate in Upcoming Investor Conference in SeptemberGlobeNewsWire • 09/04/19
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct OfferingGlobeNewsWire • 08/23/19
Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)GlobeNewsWire • 08/22/19
Seelos' Gene Therapy Acquisition For Parkinson's Disease Brings Another Shot On GoalSeeking Alpha • 07/10/19